Bioxytran, Inc financial data

Symbol
BIXT on OTC
Location
Needham, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 0.26 % -79.4%
Return On Equity 93.8 % -46.7%
Return On Assets -1.63K % +18.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 99.1M shares +15.5%
Common Stock, Shares, Outstanding 89M shares +8.21%
Entity Public Float 8M USD -13%
Common Stock, Value, Issued 89K USD +8.21%
Weighted Average Number of Shares Outstanding, Basic 89M shares -29.6%
Weighted Average Number of Shares Outstanding, Diluted 89M shares -29.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 103K USD
General and Administrative Expense 648K USD -28.4%
Operating Income (Loss) -1.72M USD +37.1%
Nonoperating Income (Expense) -630K USD -328%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -2.35M USD +15.9%
Net Income (Loss) Attributable to Parent -2.35M USD +14.8%
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 14.5K USD -58.2%
Assets 156K USD -1.71%
Accounts Payable, Current 201K USD
Liabilities, Current 3.06M USD +146%
Liabilities 3.06M USD +146%
Retained Earnings (Accumulated Deficit) -20.5M USD -12.2%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -2.9M USD -168%
Liabilities and Equity 156K USD -1.71%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -167K USD -52.7%
Net Cash Provided by (Used in) Financing Activities 167K USD +67.4%
Net Cash Provided by (Used in) Investing Activities -6K USD -27.3%
Common Stock, Shares Authorized 400M shares +33.3%
Common Stock, Shares, Issued 89M shares +8.21%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Interest Paid, Excluding Capitalized Interest, Operating Activities 164K USD +212%
Deferred Tax Assets, Valuation Allowance 3.28M USD +19.3%
Deferred Tax Assets, Gross 3.28M USD +19.3%
Deferred Tax Assets, Operating Loss Carryforwards 15.6M USD +19.3%
Preferred Stock, Shares Issued 43.4M shares +50.3%
Preferred Stock, Shares Authorized 50M shares 0%
Additional Paid in Capital 17.5M USD
Preferred Stock, Shares Outstanding 43.4M shares +50.3%
Amortization of Intangible Assets 11.5K USD +29.3%
Share-based Payment Arrangement, Expense 28.6K USD -90.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%